Wolf Herman Fridman
Overview
Explore the profile of Wolf Herman Fridman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
10924
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Fridman W, Petitprez F, Meylan M, Chen T, Sun C, Roumenina L, et al.
J Exp Med
. 2021 Feb;
218(1).
PMID: 33601413
Whereas T cells have been considered the major immune cells of the tumor microenvironment able to induce tumor regression and control cancer clinical outcome, a burst of recent publications pointed...
12.
Sautes-Fridman C, Verneau J, Sun C, Moreira M, Chen T, Meylan M, et al.
Semin Immunol
. 2020 Nov;
48:101406.
PMID: 33248905
Tumors progression is under the control of a heterogeneous microenvironment composed of immune cells, fibroblasts, blood and lymphatic vessels, in which T cells have been demonstrated to be major actors,...
13.
Wischhusen J, Melero I, Fridman W
Front Immunol
. 2020 Jun;
11:951.
PMID: 32508832
Growth/differentiation factor-15 (GDF-15), also named macrophage inhibitory cytokine-1, is a divergent member of the transforming growth factor β superfamily. While physiological expression is barely detectable in most somatic tissues in...
14.
Fridman W, Petitprez F, Sautes-Fridman C
Bull Cancer
. 2020 Apr;
107(4):403-404.
PMID: 32284150
No abstract available.
15.
Helmink B, Reddy S, Gao J, Zhang S, Basar R, Thakur R, et al.
Nature
. 2020 Jan;
577(7791):549-555.
PMID: 31942075
Treatment with immune checkpoint blockade (ICB) has revolutionized cancer therapy. Until now, predictive biomarkers and strategies to augment clinical response have largely focused on the T cell compartment. However, other...
16.
Roumenina L, Daugan M, Petitprez F, Sautes-Fridman C, Fridman W
Nat Rev Cancer
. 2019 Nov;
19(12):698-715.
PMID: 31666715
The tumour microenvironment (TME) highly influences the growth and spread of tumours, thus impacting the patient's clinical outcome. In this context, the complement system plays a major and complex role....
17.
Sautes-Fridman C, Petitprez F, Calderaro J, Fridman W
Nat Rev Cancer
. 2019 May;
19(6):307-325.
PMID: 31092904
Tertiary lymphoid structures (TLSs) are ectopic lymphoid organs that develop in non-lymphoid tissues at sites of chronic inflammation including tumours. Key common characteristics between secondary lymphoid organogenesis and TLS neogenesis...
18.
Ijsselsteijn M, Petitprez F, Lacroix L, Ruano D, van der Breggen R, Julie C, et al.
Br J Cancer
. 2019 Mar;
120(8):815-818.
PMID: 30862951
In colorectal cancer (CRC), T-cell checkpoint blockade is only effective in patients diagnosed with mismatch repair-deficient (MMR-d) cancers. However, defects in Human Leukocyte Antigen (HLA) class I expression were reported...
19.
Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, et al.
J Immunother Cancer
. 2018 Dec;
6(1):139.
PMID: 30526667
A high density of tumor-infiltrating CD8 T cells and CD20 B cells correlates with prolonged survival in patients with a wide variety of human cancers, including high-grade serous ovarian carcinoma...
20.
Giraldo N, Sanchez-Salas R, Peske J, Vano Y, Becht E, Petitprez F, et al.
Br J Cancer
. 2018 Nov;
120(1):45-53.
PMID: 30413828
The highly complex and heterogenous ecosystem of a tumour not only contains malignant cells, but also interacting cells from the host such as endothelial cells, stromal fibroblasts, and a variety...